This site uses cookies to improve your experience. To help us insure we adhere to various privacy regulations, please select your country/region of residence. If you do not select a country, we will assume you are from the United States. Select your Cookie Settings or view our Privacy Policy and Terms of Use.
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Used for the proper function of the website
Used for monitoring website traffic and interactions
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Strictly Necessary: Used for the proper function of the website
Performance/Analytics: Used for monitoring website traffic and interactions
KarXT targets both the M1 and M4 muscarinic receptors, resulting in a differentiated safety and efficacy profile. Currently under review by the US Food and DrugAdministration (FDA), KarXT is expected to launch in the US in late 2024.
This recent decision by the EC follows approval of Tyruko ® (natalizumab) by the US Food and DrugAdministration (FDA) last month for the same indication. Polpharma Biologics will maintain responsibilities for development of medicine, manufacturing and supply of drug substance.
Venture investment skyrocketed, partnerships between leading AI startups and health systems took shape, and policymakers across the globe grappled with AIs implications for consumer safety and algorithmic transparency. Want to stay up to date on the latest changes in statewide regulatory changes?
We organize all of the trending information in your field so you don't have to. Join 8,000+ users and stay up to date on the latest articles your peers are reading.
You know about us, now we want to get to know you!
Let's personalize your content
Let's get even more personalized
We recognize your account from another site in our network, please click 'Send Email' below to continue with verifying your account and setting a password.
2026 
98 
Let's personalize your content